Stock 2197 CLOVER BIOPHARMACEUTICALS, LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Clover Biopharmaceuticals, Ltd. Share Price

Equities

2197

KYG2280A1076

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 09:08:22 29/04/2024 BST 		5-day change 1st Jan Change
0.345 HKD -4.17% Intraday chart for Clover Biopharmaceuticals, Ltd. +4.55% -44.35%
04-12 Clover Biopharmaceuticals, Ltd. announced that it has received $0.320713 million in funding CI
04-08 Clover Biopharmaceuticals' RSV Vaccine Candidate Shows Promise in Early Trial MT

Financials

Sales 2021 - Sales 2022 - Capitalization 2.96B 23.14B 236B
Net income 2021 -6.02B -47.09B -480B Net income 2022 -2.45B -19.19B -196B EV / Sales 2021 -
Net cash position 2021 2.79B 21.85B 223B Net cash position 2022 1.27B 9.94B 101B EV / Sales 2022 -
P/E ratio 2021
-2.13 x
P/E ratio 2022
-1.03 x
Employees 387
Yield 2021 *
-
Yield 2022
-
Free-Float 48.91%
More Fundamentals * Assessed data

Chart Clover Biopharmaceuticals, Ltd.

Dynamic Chart

Latest news about Clover Biopharmaceuticals, Ltd.

Clover Biopharmaceuticals, Ltd. announced that it has received $0.320713 million in funding CI
Clover Biopharmaceuticals' RSV Vaccine Candidate Shows Promise in Early Trial MT
Clover Biopharmaceuticals, Ltd. Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 In Initial Young Adult Cohort CI
Clover Biopharmaceuticals, Ltd. announced that it expects to receive $0.320713 million in funding CI
Clover Biopharmaceuticals Trims Losses in 2023 MT
Clover Biopharmaceuticals, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Sinovac Halts Production of COVID-19 Vaccine as Demand Wanes MT
Clover Biopharmaceuticals Publishes Positive Results from SCB-219M Clinical Trial MT
Clover Biopharmaceuticals, Ltd. Announces Positive Phase I Results for SCB-219M for Treatment of Chemotherapy-Induced Thrombocytopenia CI
Clover Biopharmaceuticals Completes Patient Enrollment for Australia Phase 1 Trial; Shares Fall 5% MT
Clover Biopharmaceuticals, Ltd. Initiates Phase Clinical Trial for RSV Vaccine Candidate CI
Clover Biopharmaceuticals Completes Submission of Application for Seasonal Flu Vaccine in Brazil MT
Clover Biopharmaceuticals, Ltd. Completes Biologic License Application for Its Seasonal Influenza Vaccine in Brazil CI
Clover Biopharmaceuticals Rolls Out Quadrivalent Seasonal Influenza Vaccine in Mainland China MT
Clover Launches Quadrivalent Seasonal Influenza Vaccine in Mainland China CI
More news

Press releases Clover Biopharmaceuticals, Ltd.

Clover Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Initial Young Adult Cohort PR
Clover Announces Positive Phase ? Results for SCB-219M for Treatment of Chemotherapy-Induced Thrombocytopenia (CIT) AQ
Clover Initiates Phase Ⅰ Clinical Trial for RSV Vaccine Candidate PR
Clover Launches Quadrivalent Seasonal Influenza Vaccine in Mainland China GL
Clover Launches Quadrivalent Seasonal Influenza Vaccine in Mainland China AQ
More press releases

Quotes and Performance

1 day-4.17%
1 week+4.55%
Current month-15.85%
1 month-13.75%
3 months-23.33%
6 months-47.73%
Current year-44.35%
More quotes

Highs and lows

1 week
0.31
Extreme 0.31
0.37
1 month
0.30
Extreme 0.3
0.43
Current year
0.30
Extreme 0.3
0.63
1 year
0.30
Extreme 0.3
1.85
3 years
0.30
Extreme 0.3
14.80
5 years
0.30
Extreme 0.3
14.80
10 years
0.30
Extreme 0.3
14.80
More quotes

Managers and Directors - Clover Biopharmaceuticals, Ltd.

Managers TitleAgeSince
Joshua Liang CEO
 Chief Executive Officer - 24/12/20
Aileen Wang DFI
 Director of Finance/CFO - 28/02/21
Htay Htay Han CTO
 Chief Tech/Sci/R&D Officer 56 02/02/21
Members of the board TitleAgeSince
Jeffrey Farrow BRD
 Director/Board Member 62 18/04/21
Xiao Dong Wang BRD
 Director/Board Member 61 15/03/21
Xiao Bin Wu BRD
 Director/Board Member 62 18/04/21
More insiders

ETFs positioned on Clover Biopharmaceuticals, Ltd.

Name Weight AuM 1st Jan change Investor Rating
LONCAR CHINA BIOPHARMA ETF - DISTRIBUTING - USD ETF Loncar China BioPharma ETF - Distributing - USD
0.69% 4 M€ -27.92%
More ETFs positioned on Clover Biopharmaceuticals, Ltd.

Quotes

Date Price Change Volume
29/04/24 0.345 -4.17% 924 000
26/04/24 0.36 +9.09% 1,900,000
25/04/24 0.33 +3.13% 1,362,000
24/04/24 0.32 -3.03% 2,310,500
23/04/24 0.33 0.00% 589,500

Delayed Quote Hong Kong S.E., April 29, 2024 at 09:08 am

More quotes

Company Profile

Clover Biopharmaceuticals Ltd is a China-based company mainly engaged in pharmaceutical business. The Company's main business is the development of new vaccines and biotherapeutic candidates for infectious diseases, cancer and autoimmune diseases. The Company's products are mainly used to treat the new coronavirus, malignant ascites, and ankylosing spondylitis.
Sector
Biotechnology & Medical Research
Calendar
20/08/2024 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
CLOVER BIOPHARMACEUTICALS, LTD. Stock Clover Biopharmaceuticals, Ltd.
-44.35% 59.65M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+0.79% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-8.40% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 2197 Stock